You previously had great success with InnoPharma, which was eventually sold to Pfizer. Could you provide some insight into your new venture, Nevakar?
InnoPharma’s acquisition was a strategic move by Pfizer; its product pipeline and track record of successfully developing and commercializing complex generic injectable products provided Pfizer a platform for further growth in this area. This was a great exit for InnoPharma’s shareholders as well as its team. After completing integration, I left Pfizer to found Nevakar in 2015.
